Home » Topics » Regulatory » NMPA

NMPA
RSS

Calcium channel blocker for hypertension clear to enter clinical testing in China

March 14, 2012

Antisense Therapeutics to form joint venture for development of ATL-1102

Feb. 29, 2012

Ready-to-use oral therapy approved in China for oral mucositis in patients with cancer

Feb. 28, 2012

Milestone developments for Novartis' Lucentis and Galvus in China

Jan. 19, 2012

F-647 approved in China

Sep. 22, 2011

First iguratimod product approved in China

Aug. 26, 2011

High-dose EPIAO approved in China to treat chemotherapy-associated anemia

July 14, 2011

Chinese health authorities approve Novo Nordisk's Victoza for type 2 diabetes

March 16, 2011

Hutchison MediPharma begins phase I trial of fruquintinib in China

Feb. 2, 2011

TPIAO approved in China for idiopathic thrombocytopenic purpura

Jan. 26, 2011

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...